Senseonics announces 1-for-20 reverse stock split and share reduction

Senseonics Holdings, Inc. (NYSE American:SENS), a medical technology company currently trading at $0.42 per share, announced on Thursday that it will implement a 1-for-20 reverse stock split of its outstanding common stock and reduce its authorized shares from 1.4 billion to 70 million. According to InvestingPro analysis, the company holds more cash than debt on its balance sheet and appears undervalued based on Fair Value estimates. The changes will take effect at 4:05 p.m. Eastern Time on Friday.

According to a statement in an SEC filing, the reverse stock split means every 20 shares of Senseonics common stock outstanding will be automatically combined into one share, with no change to the par value per share. The authorized number of shares will also be proportionally reduced. With a current market capitalization of $342 million and a strong current ratio of 9.58, InvestingPro data shows the company maintains healthy liquidity with assets well exceeding short-term obligations.

All stock options, restricted stock unit awards, warrants, and shares reserved under the company’s equity compensation plans will be adjusted to reflect the reverse split. The exercise price of options will increase proportionally, and the number of shares issuable upon exercise or vesting will decrease accordingly.

No fractional shares will be issued. Stockholders who would otherwise receive a fractional share will instead receive a cash payment for the fractional amount. The company stated that the reverse stock split will affect all stockholders proportionately and will not change any stockholder’s percentage ownership, except for adjustments related to fractional shares.

Senseonics common stock is expected to begin trading on a split-adjusted basis on the NYSE American at the start of trading on Monday under the existing ticker symbol SENS. The stock has seen a 24.72% price return over the past year, despite being down 25.43% over the last six months. The new CUSIP number for the post-split common stock will be 81727U303. For deeper insights into SENS’s financial health and growth prospects, investors can access comprehensive analysis through InvestingPro, which offers exclusive ProTips and detailed financial metrics for over 1,400 US stocks.

This information is based on a press release statement included in the company’s recent SEC filing.

In other recent news, Senseonics Holdings reported its second-quarter 2025 financial results, with net revenue reaching $6.6 million, surpassing the forecasted $6.01 million. Despite the revenue beat, earnings per share remained at a loss of $0.02, aligning with expectations. The company announced a strategic shift in its distribution agreement, with Ascensia Diabetes Care set to transfer commercialization activities for the Eversense 365 product back to Senseonics by January 2026. This change has been met with positive analyst reactions, as H.C. Wainwright reiterated a Buy rating and Mizuho maintained an Outperform rating for the company. Barclays initiated coverage with an Overweight rating, highlighting the potential of Senseonics’ implantable continuous glucose monitoring system. Meanwhile, Raymond James maintained an Underperform rating, noting that the second-quarter revenue slightly exceeded its estimates, but the full-year 2025 revenue guidance remains unchanged. These developments reflect ongoing shifts in Senseonics’ strategic positioning and market reach.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.